LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
LIXTE Biotechnology Holdings, Inc. signs exclusive patent license agreement with NIH to develop innovative cancer immunotherapies. The collaboration aims to combine LIXTE's LB-100 with various cancer treatments to enhance anti-cancer activity. Clinical trials are underway to evaluate LB-100's potential in combination with checkpoint inhibitors and chemotherapy for cancer treatment.
The exclusive patent license agreement between LIXTE Biotechnology Holdings and the National Institutes of Health represents a strategic move in the field of oncology. The focus on LB-100 as a PP2A inhibitor offers a novel approach to cancer treatment, particularly in enhancing the efficacy of existing immunotherapies. PP2A is an enzyme that regulates various cellular functions, including cell growth and division. Inhibiting PP2A can potentially disrupt cancer cell proliferation, making LB-100 a promising adjunct to immunotherapy.
Checkpoint inhibitors, such as PD-1 blockers, have revolutionized cancer treatment by enabling the immune system to recognize and attack tumor cells. However, not all patients respond to these therapies. LB-100's potential to enhance the effectiveness of drugs like dostarlimab-gxly in ovarian clear cell carcinoma and atezolizumab in small cell lung cancer, could lead to significant advancements in treatment outcomes. As clinical trials progress, the oncology community will be closely monitoring efficacy and safety data, which will be critical for understanding LB-100's role in cancer therapy.
LIXTE's partnership with NINDS and NCI is a testament to the company's dedication to pioneering cancer research. By securing exclusive rights to NIH's intellectual property for LB-100, LIXTE gains a competitive advantage in the development of combination therapies. This collaboration could accelerate the translation of research into clinical applications, potentially benefiting patients with limited treatment options.
The initiation of Phase 1b/2 clinical trials is a crucial step in determining the safety and optimal dosing of LB-100 when combined with other cancer therapies. The success of these trials can impact LIXTE's market valuation and investor confidence, especially if LB-100 demonstrates a clear benefit in enhancing immunotherapy response rates. Moreover, the ability to secure patents and exclusive licensing agreements is indicative of a company's innovative capacity and strategic foresight in a highly competitive pharmaceutical landscape.
The strategic collaboration between LIXTE and federal research institutions may have a significant impact on the company's market position. The focus on developing combination therapies aligns with current trends in personalized medicine and targeted cancer treatments. If LB-100 proves to be effective in enhancing the efficacy of checkpoint inhibitors and chemotherapy, it could capture a substantial share of the cancer treatment market.
Investors will be interested in the progress of the ongoing clinical trials, as positive outcomes could lead to an increase in LIXTE's stock value. The company's ability to navigate the complex regulatory environment and successfully bring LB-100 to market will be critical in determining its long-term financial success. As the trials advance and more data becomes available, the potential market impact of LB-100 will become clearer, influencing investment decisions in the biotechnology sector.
02/26/2024 - 08:30 AM
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies
PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
Under the terms of the license agreement, LIXTE has licensed exclusively NIH’s intellectual property rights claimed for a Cooperative Research and Development Agreement (CRADA) subject invention co-developed with Lixte, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
“This strategic collaboration marks a significant milestone in advancing LIXTE's mission to advance cancer therapy by developing its first-in-class lead clinical PP2A inhibitor, LB-100, as a potentiator of cancer immunotherapy,” said Bas van der Baan, Chief Executive Officer of LIXTE. “We are excited to embark on this journey as it opens up new avenues for advancing our commitment to developing effective and targeted anti-cancer therapies. The agreement reinforces our dedication to pioneering research and delivering innovative solutions to patients battling cancer," he added.
The collaboration harnesses the synergies of LIXTE’s innovative compound, LB-100, and NINDS's and NCI’s cutting-edge research capabilities. The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.
LIXTE recently announced the entry of the first patient into a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, has the ability to enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC) . Another Phase 1b clinical trial in small cell lung cancer combining LB-100 with Roche’s atezolizumab and chemotherapy is also actively recruiting . The Company intends to develop additional clinical trials with LB-100 to enhance the efficacy of chemotherapy and immunotherapy.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com ), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov . The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, Contact: info@lixte.com
or
PondelWilkinson Inc. Investor Relationspwinvestor@pondel.com
What is the focus of the agreement between LIXTE and NIH?
The agreement focuses on combining LIXTE's LB-100 with various innovative cancer immunotherapies to promote anti-cancer activity.
What is the scope of the clinical research mentioned in the press release?
The clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
Which clinical trials are currently ongoing with LB-100?
LIXTE is conducting Phase 1b/2 clinical trials to assess LB-100's effectiveness in combination with GSK's PD-1-blocking monoclonal antibody for ovarian clear cell carcinoma, and with Roche's atezolizumab and chemotherapy for small cell lung cancer.
What is LIXTE's goal with the development of additional clinical trials?
LIXTE intends to develop additional clinical trials with LB-100 to enhance the efficacy of chemotherapy and immunotherapy.
